Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKD3 | O94806 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.53 |
| ▸ | SRC | P12931 | 7/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32659748 | 1.00 | PRKD3 (0.61) | PRKD3KCNH2SRCABL1LCK | |
| SCHEMBL23630581 | 0.89 | SRC (0.53) | PRKD3KCNH2SRCABL1LCK | |
| SCHEMBL32659753 | 0.89 | SRC (0.53) | PRKD3KCNH2SRCABL1LCK | |
| SCHEMBL17962901 | 0.87 | PRKD3 (0.62) | PRKD3KCNH2SRCABL1LCK | |
| SCHEMBL17962892 | 0.87 | PRKD3 (0.78) | PRKD3KCNH2SRCABL1LCK | |
| SCHEMBL23630546 | 0.82 | PRKD3 (0.42) | PRKD3KCNH2SRCABL1 | |
| SCHEMBL32659767 | 0.82 | PRKD3 (0.42) | PRKD3KCNH2SRCABL1 | |
| SCHEMBL21165331 | 0.79 | PRKD3 (0.66) | PRKD3KCNH2SRCABL1LCK | |
| SCHEMBL17962812 | 0.79 | KCNH2 (0.67) | PRKD3KCNH2SRCABL1LCK | |
| SCHEMBL17963662 | 0.78 | KCNH2 (0.64) | PRKD3KCNH2SRCABL1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230125057-A1 | Modified Pyrrolo- and Pyrazolo- Pyrimidines for Prostate Cancer Therapy | UNIVERSITY OF WASHINGTON | 2023-04-20 | — | — | US | disclosed |
| WO-2021142170-A1 | MODIFIED PYRROLO- AND PYRAZOLO- PYRIMIDINES FOR PROSTATE CANCER THERAPY | UNIVERSITY OF WASHINGTON (US) | 2021-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230125057-A1 | Modified Pyrrolo- and Pyrazolo- Pyrimidines for Prostate Cancer Therapy | PDK2, PDK1, PC | PRKD3 355/4885KCNH2 4377/4885SRC 1546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.